Switch theme
Sign up to access all valuation multiples
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earns revenues from contracts with patients in which the performance obligations are to provide health care services.
2015
15K+
LTM Revenue $3.2B
LTM EBITDA $530M
$6.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Surgery Partners has a last 12-month revenue (LTM) of $3.2B and a last 12-month EBITDA of $530M.
In the most recent fiscal year, Surgery Partners achieved revenue of $3.1B and an EBITDA of $501M.
Surgery Partners expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Surgery Partners valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.2B | XXX | $3.1B | XXX | XXX | XXX |
| Gross Profit | $1.1B | XXX | $746M | XXX | XXX | XXX |
| Gross Margin | 35% | XXX | 24% | XXX | XXX | XXX |
| EBITDA | $530M | XXX | $501M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| EBIT | $406M | XXX | $454M | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $125M | XXX | -$168M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | -5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $3.1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Surgery Partners's stock price is $24.
Surgery Partners has current market cap of $3.0B, and EV of $6.7B.
See Surgery Partners trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.7B | $3.0B | XXX | XXX | XXX | XXX | $0.97 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Surgery Partners has market cap of $3.0B and EV of $6.7B.
Surgery Partners's trades at 2.1x EV/Revenue multiple, and 13.3x EV/EBITDA.
Equity research analysts estimate Surgery Partners's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Surgery Partners has a P/E ratio of 24.3x.
See valuation multiples for Surgery Partners and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV (current) | $6.7B | XXX | $6.7B | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 12.6x | XXX | 13.3x | XXX | XXX | XXX |
| EV/EBIT | 16.4x | XXX | 14.7x | XXX | XXX | XXX |
| EV/Gross Profit | 6.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 24.3x | XXX | -18.0x | XXX | XXX | XXX |
| EV/FCF | 33.0x | XXX | 31.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSurgery Partners's last 12 month revenue growth is 9%
Surgery Partners's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $19K for the same period.
Surgery Partners's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Surgery Partners's rule of X is 38% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Surgery Partners and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | 25% | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 38% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $19K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Surgery Partners acquired XXX companies to date.
Last acquisition by Surgery Partners was XXXXXXXX, XXXXX XXXXX XXXXXX . Surgery Partners acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Surgery Partners founded? | Surgery Partners was founded in 2015. |
| Where is Surgery Partners headquartered? | Surgery Partners is headquartered in United States of America. |
| How many employees does Surgery Partners have? | As of today, Surgery Partners has 15K+ employees. |
| Who is the CEO of Surgery Partners? | Surgery Partners's CEO is Mr. J. Eric Evans. |
| Is Surgery Partners publicy listed? | Yes, Surgery Partners is a public company listed on NAS. |
| What is the stock symbol of Surgery Partners? | Surgery Partners trades under SGRY ticker. |
| When did Surgery Partners go public? | Surgery Partners went public in 2015. |
| Who are competitors of Surgery Partners? | Similar companies to Surgery Partners include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of Surgery Partners? | Surgery Partners's current market cap is $3.0B |
| What is the current revenue of Surgery Partners? | Surgery Partners's last 12 months revenue is $3.2B. |
| What is the current revenue growth of Surgery Partners? | Surgery Partners revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Surgery Partners? | Current revenue multiple of Surgery Partners is 2.1x. |
| Is Surgery Partners profitable? | Yes, Surgery Partners is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Surgery Partners? | Surgery Partners's last 12 months EBITDA is $530M. |
| What is Surgery Partners's EBITDA margin? | Surgery Partners's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Surgery Partners? | Current EBITDA multiple of Surgery Partners is 12.6x. |
| What is the current FCF of Surgery Partners? | Surgery Partners's last 12 months FCF is $202M. |
| What is Surgery Partners's FCF margin? | Surgery Partners's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Surgery Partners? | Current FCF multiple of Surgery Partners is 33.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
